-$0.22 EPS Expected for Fate Therapeutics Inc (FATE) This Quarter
Analysts expect Fate Therapeutics Inc (NASDAQ:FATE) to post ($0.22) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Four analysts have issued estimates for Fate Therapeutics’ earnings. The highest EPS estimate is ($0.21) and the lowest is ($0.24). Fate Therapeutics reported earnings of ($0.21) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 4.8%. The company is expected to announce its next quarterly earnings results after the market closes on Monday, March 5th.
On average, analysts expect that Fate Therapeutics will report full-year earnings of ($0.95) per share for the current year, with EPS estimates ranging from ($0.97) to ($0.94). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.80) per share, with EPS estimates ranging from ($0.84) to ($0.72). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research firms that follow Fate Therapeutics.
A number of research firms have issued reports on FATE. ValuEngine upgraded Fate Therapeutics from a “sell” rating to a “hold” rating in a research note on Friday, December 22nd. Zacks Investment Research cut Fate Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, January 22nd. Wedbush reiterated an “outperform” rating and issued a $7.00 target price (down from $10.00) on shares of Fate Therapeutics in a research note on Thursday, January 18th. BidaskClub upgraded Fate Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, January 23rd. Finally, Piper Jaffray Companies began coverage on Fate Therapeutics in a research note on Monday, December 18th. They issued an “overweight” rating and a $10.00 target price on the stock. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $7.71.
Shares of Fate Therapeutics (NASDAQ FATE) opened at $13.27 on Thursday. The company has a quick ratio of 7.21, a current ratio of 7.21 and a debt-to-equity ratio of 0.32. The stock has a market capitalization of $676.53, a price-to-earnings ratio of -14.12 and a beta of 1.65. Fate Therapeutics has a one year low of $2.52 and a one year high of $14.03.
COPYRIGHT VIOLATION NOTICE: “-$0.22 EPS Expected for Fate Therapeutics Inc (FATE) This Quarter” was first published by Watch List News and is owned by of Watch List News. If you are reading this news story on another domain, it was copied illegally and republished in violation of US and international copyright law. The legal version of this news story can be accessed at https://www.watchlistnews.com/0-22-eps-expected-for-fate-therapeutics-inc-fate-this-quarter/1906711.html.
Fate Therapeutics Company Profile
Fate Therapeutics, Inc (Fate Therapeutics) is a clinical-stage biopharmaceutical company. The Company is engaged in development of programmed cellular immunotherapies for cancer and immune disorders. The Company’s cell therapy pipeline consists of immuno-oncology programs, including cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Fate Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fate Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.